@agewellmd's TRT fertility warning, fact-checked

What did @agewellmd actually say?

The creator made three core claims: that starting TRT young may mean "a lifelong treatment," that TRT can put fertility "at risk," and that drugs like "Clomid, Ganirelix (Ganatorellin), and possibly HCG" can preserve fertility alongside testosterone. The advice was directed specifically at men in their 20s and 30s considering TRT, which is a narrower and more clinically relevant audience than most TRT content targets.

This is not the usual bro-science TRT content. The creator actually told young men to dig into why their testosterone is low before starting therapy, which is genuinely good advice that most TikTok testosterone content skips entirely. The framing is cautionary, not promotional, which puts it in a different category from a lot of what circulates on this topic.

Does the science back this up?

Yes, on the fertility point, the evidence is solid and has been for decades. Exogenous testosterone suppresses the hypothalamic-pituitary-gonadal (HPG) axis. That suppression reduces LH and FSH, which in turn drops intratesticular testosterone and leads to impaired spermatogenesis. This is not controversial.

Contraception researchers have actually studied this effect intentionally. The World Health Organization ran trials in the 1990s using testosterone as a male contraceptive, achieving azoospermia or severe oligospermia in a substantial proportion of participants (WHO Task Force, 1990, Lancet). More recent data from Coward et al. (2013, Journal of Urology) found that men on exogenous testosterone had significantly lower sperm concentrations compared to controls, with many reaching azoospermia. The suppression is often reversible after stopping TRT, but recovery is not guaranteed, and it can take months to over a year.

The claim that young men may be committing to lifelong treatment is also defensible. If TRT suppresses endogenous production over time, particularly in men whose hypothalamic-pituitary axis is still relatively functional, the likelihood of recovering baseline testosterone after years of exogenous use decreases. This is not well-studied in long-term prospective trials, but clinically it is a recognized concern.

What did they get wrong (or right)?

The creator gets the fertility risk right. Where things get murkier is in the shorthand mention of "Ganatorellin" as a fertility-preservation option. Gonadorelin and kisspeptin analogs are being used in clinical practice for this purpose, but Ganatorellin specifically is a compounded GnRH agonist with limited peer-reviewed data compared to HCG or clomiphene. Lumping it in with HCG and Clomid as roughly equivalent options glosses over the fact that the evidence bases are not the same size.

Clomiphene citrate (Clomid) has reasonable data supporting its use for preserving or restoring spermatogenesis in men on TRT. Wenker et al. (2015, Journal of Urology) found clomiphene effective at maintaining testosterone while preserving fertility markers. HCG has a longer track record still, acting as an LH analog to stimulate intratesticular testosterone production and support sperm production. The evidence for compounded Ganatorellin is thinner. That distinction matters clinically and was not made here.

The advice to "really get to the core" of why testosterone is low before starting therapy is genuinely correct and underemphasized in most TRT content. Secondary causes like sleep apnea, obesity, or pituitary pathology can be addressed without lifelong hormone replacement.

What should you actually know?

If you are a man under 40 considering TRT and you want biological children, this is one of the most important conversations to have with a physician before starting, not after. Sperm banking before initiating TRT is a simple, low-cost option that provides insurance regardless of which fertility-preservation protocol you use alongside therapy.

The reversibility of TRT-induced suppression is real but not guaranteed. Liu et al. (2006, Journal of Clinical Endocrinology and Metabolism) found that recovery of spermatogenesis after testosterone-induced suppression took a median of 3-4 months but was not universal. Age, duration of use, and baseline fertility all appear to affect recovery odds.

Any fertility-preservation protocol, whether HCG, clomiphene, or a GnRH analog like gonadorelin, should be managed by a physician with endocrine or urology training, not self-directed. These are not supplements. Dosing and monitoring matter, and the compounded versions of these drugs are not clinically equivalent to their studied counterparts. The creator wisely says to talk to your doctor. That part should be taken literally.